ATE557036T1 - Ox40 rezeptor bindende agenzien - Google Patents
Ox40 rezeptor bindende agenzienInfo
- Publication number
- ATE557036T1 ATE557036T1 AT03730172T AT03730172T ATE557036T1 AT E557036 T1 ATE557036 T1 AT E557036T1 AT 03730172 T AT03730172 T AT 03730172T AT 03730172 T AT03730172 T AT 03730172T AT E557036 T1 ATE557036 T1 AT E557036T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor binding
- binding agents
- agents
- receptor
- binding
- Prior art date
Links
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 title 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02100334 | 2002-04-03 | ||
| PCT/EP2003/050089 WO2003082919A2 (en) | 2002-04-03 | 2003-04-02 | Ox40r binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE557036T1 true ATE557036T1 (de) | 2012-05-15 |
Family
ID=28459562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03730172T ATE557036T1 (de) | 2002-04-03 | 2003-04-02 | Ox40 rezeptor bindende agenzien |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7758852B2 (de) |
| EP (1) | EP1492813B1 (de) |
| JP (1) | JP4426315B2 (de) |
| AR (1) | AR039231A1 (de) |
| AT (1) | ATE557036T1 (de) |
| AU (1) | AU2003240761B2 (de) |
| CA (1) | CA2480694A1 (de) |
| ES (1) | ES2387767T3 (de) |
| IL (1) | IL164376A0 (de) |
| WO (1) | WO2003082919A2 (de) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007509063A (ja) | 2003-10-17 | 2007-04-12 | ベイラー カレッジ オブ メディスン | Cd8+細胞傷害性t細胞応答を増大させる方法、および多発性硬化症を処置するための方法 |
| AT412785B (de) * | 2003-12-04 | 2005-07-25 | Kungl Andreas J Dr | Gag-bindungsproteine |
| US7812133B2 (en) | 2005-12-16 | 2010-10-12 | Genentech, Inc | Anti-OX40L antibodies and methods using same |
| US20110008368A1 (en) * | 2006-01-13 | 2011-01-13 | Board Of Regents, The University Of Texas System | Methods of modulating the ox40 receptor to treat cancer |
| CA2656923A1 (en) * | 2006-06-21 | 2007-12-27 | Genentech, Inc. | Crystal structures of ox40l and ox40l complexed with ox40 receptor |
| US9347947B2 (en) * | 2009-03-12 | 2016-05-24 | Siemens Healthcare Diagnostics Inc. | Immunoassays employing non-particulate chemiluminescent reagent |
| LT2609118T (lt) | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| JP6038920B2 (ja) * | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ox40抗体およびそれを使用する方法 |
| WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US20140294792A1 (en) * | 2013-02-22 | 2014-10-02 | The Board Of Trustees Of The University Of Illinois | T-REG Cell Expansion |
| US10696946B2 (en) | 2013-02-22 | 2020-06-30 | The Board Of Trustees Of The University Of Illinois | T-REG cell expansion |
| JP2017165652A (ja) * | 2014-06-30 | 2017-09-21 | 国立大学法人東北大学 | 新規抗ヒトox40リガンド抗体、及びこれを含む抗インフルエンザ薬 |
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| US10046047B2 (en) | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| CA2975432A1 (en) | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| EP3331919A1 (de) | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationstherapie mit anti-ctla-4-antikörpern |
| ES2913208T3 (es) | 2015-12-01 | 2022-06-01 | Glaxosmithkline Ip Dev Ltd | Tratamientos de combinación y usos y métodos de los mismos |
| JP6411676B2 (ja) | 2015-12-03 | 2018-10-24 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | Stingの調節因子としての環状プリンジヌクレオチド |
| WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| SG10201900628RA (en) | 2016-04-07 | 2019-02-27 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides useful as protein modulators |
| WO2017191545A1 (en) | 2016-05-05 | 2017-11-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Enhancer of zeste homolog 2 inhibitors |
| CN109789135A (zh) | 2016-07-20 | 2019-05-21 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为perk抑制剂的异喹啉衍生物 |
| EP3494140A1 (de) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos- und anti-pd-1-antikörper-kombinationstherapie |
| US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
| WO2018100535A1 (en) | 2016-12-01 | 2018-06-07 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
| EP3548069A1 (de) | 2016-12-01 | 2019-10-09 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationstherapie |
| EP3585782A1 (de) | 2017-02-27 | 2020-01-01 | GlaxoSmithKline Intellectual Property Development Limited | Heterocyclische amide als kinaseinhibitoren |
| JP7244428B2 (ja) * | 2017-02-27 | 2023-03-22 | シャタック ラボ,インコーポレイテッド | Vsig8ベースのキメラタンパク質 |
| WO2018187260A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
| EP3635010A1 (de) | 2017-06-09 | 2020-04-15 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationstherapie mit icos-agonist und ox40-agonisten zur behandlung von krebs |
| CA3066007A1 (en) | 2017-06-09 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
| WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
| WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| US11377440B2 (en) | 2017-10-05 | 2022-07-05 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
| CN113795512A (zh) | 2019-02-01 | 2021-12-14 | 葛兰素史克知识产权开发有限公司 | 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法 |
| CA3143211A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
| GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
| WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
| AU2020355614B2 (en) | 2019-09-27 | 2024-12-05 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| WO2021119753A1 (en) | 2019-12-18 | 2021-06-24 | Ctxt Pty Limited | Compounds |
| EP4096718A1 (de) | 2020-01-28 | 2022-12-07 | GlaxoSmithKline Intellectual Property Development Limited | Kombinationsbehandlungen und verwendungen und verfahren dafür |
| CN113754778A (zh) * | 2020-06-05 | 2021-12-07 | 上海交通大学 | 靶向cldn18.2的嵌合抗原受体及其用途 |
| CA3212345A1 (en) | 2021-03-02 | 2022-09-09 | Glaxosmithkline Intellectual Property Development Limited | Substituted pyridines as dnmt1 inhibitors |
| EP4314060A1 (de) | 2021-03-31 | 2024-02-07 | GlaxoSmithKline Intellectual Property Development Limited | Antigenbindende proteine und kombinationen davon |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL106197A (en) * | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US6242566B1 (en) * | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6602856B1 (en) * | 1995-01-17 | 2003-08-05 | J. Mark Quillan | Antagonists of alpha-melanocyte stimulating hormone and methods based thereon |
| US6312700B1 (en) * | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| EP1171626A4 (de) | 1999-03-26 | 2002-10-30 | Human Genome Sciences Inc | 50 humane sekretierte proteine |
| US6872519B1 (en) * | 1999-04-27 | 2005-03-29 | Mirus Bio Corporation | In vitro process for selecting phage resistant to blood inactivation |
| EP1290217A2 (de) * | 2000-02-04 | 2003-03-12 | Aeomica, Inc. | Methoden und apparat zur voraussage, bestätigung und darstellung funktionaler information, abgeleitet von genomischen sequenzen |
| EP1383793B1 (de) * | 2000-03-29 | 2011-10-19 | DGI BioTechnologies, L.L.C. | Agonisten und antagonisten der rezeptoren des insulin und des igf-1 |
-
2002
- 2002-04-03 IL IL16437602A patent/IL164376A0/xx unknown
-
2003
- 2003-04-02 CA CA002480694A patent/CA2480694A1/en not_active Abandoned
- 2003-04-02 US US10/510,015 patent/US7758852B2/en not_active Expired - Fee Related
- 2003-04-02 AT AT03730172T patent/ATE557036T1/de active
- 2003-04-02 AU AU2003240761A patent/AU2003240761B2/en not_active Ceased
- 2003-04-02 EP EP03730172A patent/EP1492813B1/de not_active Expired - Lifetime
- 2003-04-02 ES ES03730172T patent/ES2387767T3/es not_active Expired - Lifetime
- 2003-04-02 JP JP2003580382A patent/JP4426315B2/ja not_active Expired - Fee Related
- 2003-04-02 WO PCT/EP2003/050089 patent/WO2003082919A2/en not_active Ceased
- 2003-04-02 AR ARP030101155A patent/AR039231A1/es not_active Application Discontinuation
-
2009
- 2009-11-24 US US12/624,534 patent/US7858765B2/en not_active Expired - Fee Related
-
2010
- 2010-11-23 US US12/952,226 patent/US20110086057A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1492813B1 (de) | 2012-05-09 |
| WO2003082919A3 (en) | 2004-02-05 |
| US20100136628A1 (en) | 2010-06-03 |
| US20070009964A1 (en) | 2007-01-11 |
| JP2006506041A (ja) | 2006-02-23 |
| JP4426315B2 (ja) | 2010-03-03 |
| CA2480694A1 (en) | 2003-10-09 |
| EP1492813A2 (de) | 2005-01-05 |
| IL164376A0 (en) | 2005-12-18 |
| ES2387767T3 (es) | 2012-10-01 |
| US7858765B2 (en) | 2010-12-28 |
| AU2003240761A1 (en) | 2003-10-13 |
| US20110086057A1 (en) | 2011-04-14 |
| US7758852B2 (en) | 2010-07-20 |
| WO2003082919A2 (en) | 2003-10-09 |
| AR039231A1 (es) | 2005-02-09 |
| AU2003240761B2 (en) | 2009-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE0303074L (sv) | Foganordning | |
| ATE450505T1 (de) | Cb 1 rezeptor inversagonisten | |
| NO20032486D0 (no) | Analytt-testeanordning | |
| DE60325530D1 (de) | Repositionsvorrichtung | |
| NO20034483L (no) | Tilkoblingsanordning for omradenett | |
| ATE544762T1 (de) | Calcium rezeptor modulatoren | |
| DE60333725D1 (de) | Bilderzeugungsvorrichtung | |
| DE50305428D1 (de) | Objekt-selbstschutzvorrichtung | |
| DE50201278D1 (de) | Stopfpickel | |
| DE50205514D1 (de) | Stopfpickel | |
| SE0203370L (sv) | Anordning | |
| ATA892002A (de) | Snowboardbindung | |
| DE60300310D1 (de) | Keilvorrichtung | |
| DE50309138D1 (de) | Stopfaggregat | |
| DE50300406D1 (de) | Befestigungsvorrichtung | |
| DE60328488D1 (de) | Ng | |
| DK1495030T3 (da) | Ikke-steroidale progesteronreceptormodulatorer | |
| DE50307407D1 (de) | Strömungsbremse | |
| NO20033510D0 (no) | Bindingsanordning | |
| NO20022892D0 (no) | Forankringsanordning | |
| DE50211040D1 (de) | Befestigungsvorrichtung | |
| ATA15712002A (de) | Befestigungseinrichtung | |
| SE0203561L (sv) | Anordning | |
| DE50308389D1 (de) | Befestigungseinrichtung | |
| AT6112U3 (de) | Dübel |